61 Publications (Page 1 of 3)
2022
Single-dose AAV vector gene immunotherapy to treat food allergy
Gonzalez-Visiedo, Miguel⋅Li, Xin⋅Munoz-Melero, Maite⋅Kulis, Michael D⋅Daniell, Henry and Markusic, David M
Molecular therapy. Methods & clinical development, vol. 26, pp. 309-322, Sep 8, 2022. | Journal Article
2021
Coagulation factor IX gene transfer to non-human primates using engineered AAV3 capsid and hepatic optimized expression cassette
Kumar, S.R.P.⋅Kumar, Sandeep R P⋅Kumar, Sandeep R P⋅Xie, Jun⋅Xie, J.⋅Xie, Jun⋅Hu, S.⋅Hu, Shilang⋅Hu, Shilang⋅Ko, Jihye⋅Ko, J.⋅Ko, Jihye⋅Huang, Q.⋅Huang, Qifeng⋅Huang, Qifeng⋅Brown, H.C.⋅Brown, Harrison C⋅Brown, Harrison C⋅Srivastava, Alok⋅Srivastava, Alok⋅Srivastava, A.⋅Markusic, David M⋅Markusic, David M⋅Markusic, D.M.⋅Doering, C.B.⋅Doering, Christopher B⋅Doering, Christopher B⋅Spencer, H Trent⋅Spencer, H Trent⋅Spencer, H.T.⋅Srivastava, Arun⋅Srivastava, A.⋅Srivastava, Arun⋅Gao, Guangping⋅Gao, Guangping⋅Gao, G.⋅Herzog, R.W.⋅Herzog, Roland W and Herzog, Roland W
Molecular Therapy - Methods and Clinical Development, vol. 23, pp. 98-107. | Journal Article
2020
Adeno-Associated Virus D-Sequence-Mediated Suppression of Expression of a Human Major Histocompatibility Class II Gene: Implications in the Development of Adeno-Associated Virus Vectors for Modulating Humoral Immune Response
Kwon, Hyung-Joo⋅Kwon, Hyung-Joo⋅HJ, Kwon⋅Qing, Keyun⋅Qing, Keyun⋅K, Qing⋅Ponnazhagan, Selvarangan⋅Ponnazhagan, Selvarangan⋅S, Ponnazhagan⋅Wang, Xu-Shan⋅Wang, Xu-Shan⋅XS, Wang⋅Markusic, David M⋅Markusic, David M⋅DM, Markusic⋅Gupte, Siddhant⋅Gupte, Siddhant⋅S, Gupte⋅Boye, Shannon E⋅Boye, Shannon E⋅SE, Boye⋅A, Srivastava⋅Srivastava, Arun and Srivastava, Arun
Human Gene Therapy, vol. 31, (no. 9-10), pp. 574, 2020-05-01. | Journal Article
 
B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
M, Biswas⋅B, Palaschak⋅SRP, Kumar⋅J, Rana and DM, Markusic
Frontiers in immunology. | Journal Article
 
Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B.
Human gene therapy. | Journal Article
 
Immune Response Mechanisms against AAV Vectors in Animal Models
Martino, Ashley T and Markusic, David M
Molecular Therapy - Methods & Clinical Development, vol. 17, pp. 208, 2020-06-12. | Journal Article
 
Immunology of Gene and Cell Therapy
Markusic, David M⋅Martino, Ashley T⋅Porada, Christopher D and VandenDriessche, Thierry
Molecular Therapy, vol. 28, (no. 3), pp. 692, 2020-03-04. | Journal Article
 
Type I IFN Sensing by cDCs and CD4+ T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8+ T Cells
Shirley, J.L.⋅Shirley, J.L.⋅Shirley, Jamie L⋅Keeler, G.D.⋅Keeler, Geoffrey D⋅Keeler, G.D.⋅Sherman, Alexandra⋅Sherman, A.⋅Sherman, A.⋅Zolotukhin, I.⋅Zolotukhin, I.⋅Zolotukhin, Irene⋅Markusic, D.M.⋅Markusic, D.M.⋅Markusic, David M⋅Hoffman, B.E.⋅Hoffman, B.E.⋅Hoffman, Brad E⋅Morel, Laurence M⋅Morel, L.M.⋅Morel, L.M.⋅Wallet, M.A.⋅Wallet, M.A.⋅Wallet, Mark A⋅Terhorst, C.⋅Terhorst, C.⋅Terhorst, Cox⋅Herzog, Roland W⋅Herzog, R.W. and Herzog, R.W.
Molecular Therapy, vol. 28, (no. 3), pp. 770, 2020-03-04. | Journal Article
2019
AAV-Mediated Gene Delivery to the Liver: Overview of Current Technologies and Methods
Palaschak, Brett⋅Herzog, Roland W and Markusic, David M
Methods in molecular biology (Clifton, N.J.), vol. 1950, pp. 360, 2019-00-00. | Journal Article
 
ERT Degrades Gene Therapy for Storage Disorder
Markusic, D.M.
Molecular Therapy, vol. 27, pp. 1207-1208. | Journal Article
 
Liver induced transgene tolerance with AAV vectors
Keeler, Geoffrey D⋅Keeler, G.D.⋅Keeler, G.D.⋅Markusic, D.M.⋅Markusic, D.M.⋅Markusic, David M⋅Hoffman, B.E.⋅Hoffman, Brad E and Hoffman, B.E.
Cellular Immunology, vol. 342, pp. 103728, August 2019. | Journal Article
 
Update on clinical gene therapy for hemophilia
Perrin, George Q⋅Herzog, Roland W and Markusic, David M
Blood, vol. 133, (no. 5), pp. 414, 2019-01-31. | Journal Article
2018
Gene Therapy-Induced Antigen-Specific Tregs Inhibit Neuro-inflammation and Reverse Disease in a Mouse Model of Multiple Sclerosis
Keeler, Geoffrey D⋅Keeler, G.D.⋅Keeler, G.D.⋅Kumar, S.⋅Kumar, Sandeep⋅Kumar, S.⋅Palaschak, Brett⋅Palaschak, B.⋅Palaschak, B.⋅Silverberg, E.L.⋅Silverberg, Emily L⋅Silverberg, E.L.⋅Markusic, D.M.⋅Markusic, D.M.⋅Markusic, David M⋅Jones, N.T.⋅Jones, N.T.⋅Jones, Noah T⋅Hoffman, B.E.⋅Hoffman, B.E. and Hoffman, Brad E
Molecular Therapy, vol. 26, (no. 1), pp. 183, 2018-01-03. | Journal Article
2017
An Immune-Competent Murine Model to Study Elimination of AAV-Transduced Hepatocytes by Capsid-Specific CD8 + T Cells
Palaschak, Brett⋅Marsic, Damien⋅Herzog, Roland W⋅Zolotukhin, Sergei and Markusic, David M
Molecular therapy. Methods & clinical development, vol. 5, (no. C), pp. 152, 2017-Jun-16. | Journal Article
 
Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin
Biswas, Moanaro⋅Biswas, M.⋅Biswas, Moanaro⋅Rogers, Geoffrey L⋅Rogers, Geoffrey L⋅Rogers, G.L.⋅Sherman, Alexandra⋅Sherman, A.⋅Sherman, Alexandra⋅Byrne, B.J.⋅Byrne, Barry J⋅Byrne, Barry J⋅Markusic, D.M.⋅Markusic, David M⋅Markusic, David M⋅Jiang, H.⋅Jiang, Haiyan⋅Jiang, Haiyan⋅Herzog, Roland W⋅Herzog, Roland W and Herzog, R.W.
Thrombosis and Haemostasis, vol. 117, (no. 1), pp. 43, 20170000. | Journal Article
 
Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models
Markusic, David M⋅Markusic, David M⋅Markusic, David M⋅Nichols, Timothy C⋅Nichols, Timothy C⋅Nichols, Timothy C⋅Merricks, Elizabeth P⋅Merricks, Elizabeth P⋅Merricks, Elizabeth P⋅Palaschak, Brett⋅Palaschak, Brett⋅Palaschak, Brett⋅Zolotukhin, Irene⋅Zolotukhin, Irene⋅Zolotukhin, Irene⋅Marsic, Damien⋅Marsic, Damien⋅Marsic, Damien⋅Zolotukhin, Sergei⋅Zolotukhin, Sergei⋅Zolotukhin, Sergei⋅Srivastava, Arun⋅Srivastava, Arun⋅Srivastava, Arun⋅Herzog, Roland W⋅Herzog, Roland W and Herzog, Roland W
Journal of translational medicine, vol. 15, (no. 1), pp. 94, 2017-May-01. | Journal Article
2016
688. Supplemental Immune Suppression Is Required for AAV-F8 ITI in Hemophilia A Mice with Pre-Existing Inhibitors
Markusic, David⋅Palaschak, Brett⋅Zolotukhin, Irene and Herzog, Roland
Molecular Therapy, vol. 24, pp. S273, May 2016. | Journal Article
 
Clinical development of gene therapy: results and lessons from recent successes
Kumar, Sandeep Rp⋅Kumar, Sandeep Rp⋅Markusic, David M⋅Markusic, David M⋅Biswas, Moanaro⋅Biswas, Moanaro⋅High, Katherine A⋅High, Katherine A⋅Herzog, Roland W and Herzog, Roland W
Molecular therapy. Methods & clinical development, vol. 3, (no. C), pp. 16034, 2016-00-00. | Journal Article
 
Defining the Risk of Suboptimal AAV8-F9 Vector Delivery in Inhibitor Positive Hemophilia B Mice
Markusic, David M and Palaschak, Brett
Blood, vol. 128, (no. 22), pp. 3508, 2016-12-02. | Journal Article
 
Editorial overview: Host?viral vector interactions
Herzog, R. and Markusic, D.
Current Opinion in Virology, vol. 21, pp. vii-viii. | Journal Article
 
Potential for cellular stress response to hepatic factor VIII expression from AAV vector
Zolotukhin, I.⋅Zolotukhin, Irene⋅Markusic, D.M.⋅Markusic, David M⋅Palaschak, Brett⋅Palaschak, B.⋅Hoffman, Brad E⋅Hoffman, B.E.⋅Srikanthan, Meera A⋅Srikanthan, M.A.⋅Herzog, R.W. and Herzog, Roland W
Molecular therapy. Methods & clinical development, vol. 3, (no. C), pp. 16063, 2016-00-00. | Journal Article
2015
264. Absence of CD8 T Cell Responses Against AAV Capsid Using Reduced Vector Dose or Library Selected Liver Targeted AAV2 Based Capsids
Palaschak, Brett⋅Marsic, Damien and Markusic, David M
Molecular Therapy, vol. 23, pp. S106, May 2015. | Journal Article
 
293. Optimal In Vivo Treg Induction and Suppression of Immune Responses By Synergistic Use of Rapamycin and FLT3 Ligand
Biswas, Moanaro⋅Biswas, Moanaro⋅Sarkar, Debalina⋅Sarkar, Debalina⋅Nayak, Sushrusha⋅Nayak, Sushrusha⋅Kumar, Sandeep R.P⋅Kumar, Sandeep R.P⋅Rogers, Geoffrey L⋅Rogers, Geoffrey L⋅Markusic, David M⋅Markusic, David M⋅Liao, Gongxian⋅Liao, Gongxian⋅Terhorst, Cox⋅Terhorst, Cox⋅Herzog, Roland W and Herzog, Roland W
Molecular Therapy, vol. 23, pp. S118, May 2015. | Journal Article
 
315. Optimization of the Capsid of Recombinant Adeno-Associated Virus 6 (AAV6) Vectors for Liver-, and Muscle-Directed Gene Therapy
Nolasco, Diego⋅Van Vliet, Kim⋅Markusic, David⋅Ling, Chen⋅Huang, Lin-Ya⋅Agbandje-McKenna, Mavis⋅Srivastava, Arun and Aslanidi, George
Molecular Therapy, vol. 23, pp. S127, May 2015. | Journal Article
 
Immune responses to human factor IX in haemophilia B mice of different genetic backgrounds are distinct and modified by TLR4
Sack, B.K.⋅Wang, X.⋅Sherman, A.⋅Rogers, G.L. and Markusic, D.M.
Haemophilia, vol. 21, pp. 133-139. | Journal Article